Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1762 • ACR Convergence 2022
Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns
Mark Rudolph, Rory Bloch, Anja Kammesheidt and Roberta Alexander, Exagen, Inc., Vista, CA
Background/Purpose: COVID-19 can cause autoantibody signatures in severely ill patients, and widespread emerging post-acute sequelae of SARS-CoV-2 (PASC) share many symptoms consistent with rheumatologic involvement…
Abstract Number: 2104 • ACR Convergence 2022
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Jennifer Rogers¹, Amanda Eudy², Roberta Alexander³, David Pisetsky⁴, John Conklin³, Kai Sun⁵, Lisa Criscione-Schreiber⁶, Jayanth Doss⁵, Rebecca Sadun⁵, Mithu Maheswaranathan¹ and Megan Clowse⁵, ¹Duke, Durham, NC, ²Duke University, Raleigh, NC, ³Exagen, Inc., Vista, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Manifestations of SLE can be divided into two subtypes. Type 1 SLE includes classic SLE manifestations that are driven by autoimmune inflammatory mechanisms. Type…
Abstract Number: 0034 • ACR Convergence 2022
Association of Anti-Tropomyosin Alpha-4 Autoantibodies with Cutaneous Manifestations in Juvenile Dermatomyositis
Rie Karasawa¹, James Jarvis², Toshiko Sato¹, Megumi Tanaka¹, Terrance P O'Hanlon³, Payam Noroozi-Farhadi⁴, Willy A. Flegel⁵, Kazuo Yudoh¹ and Lisa G Rider³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY, ³Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH, Garrett Park, MD
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory autoimmune diseases in children. JDM is characterized by…
Abstract Number: 0637 • ACR Convergence 2022
Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals
Carolina Munoz¹, Sindu Johnson², Zahi Touma¹, Zareen Ahmad², Dennisse Bonilla¹, Linda Hiraki³, Arthur Bookman² and Joan Wither⁴, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Currently the immune changes that lead to the transition from asymptomatic Anti-Nuclear Antibody (ANA) positivity to symptomatic disease are unknown. Studies in our laboratory…
Abstract Number: 0832 • ACR Convergence 2022
Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?
Paulo Vilas-Boas¹, Gisela Eugenio² and Anabela Barcelos², ¹Rheumatology Department, Centro Hospitalar Baixo Vouga, Aveiro, Portugal, ²Centro Hospitalar Baixo Vouga, Aveiro, Portugal
Background/Purpose: Anti-NOR 90 antibodies have been detected in inflammatory conditions, neoplastic diseases and even in healthy individuals. Despite numerous epidemiologic studies, large scale studies are…
Abstract Number: 1441 • ACR Convergence 2022
Prevalence of Secondary Connective Tissue Diseases and Autoantibodies Among Racial and Ethnic Groups in Systemic Lupus Erythematosus Patients in the Manhattan Lupus Surveillance Program
Brendan Denvir¹, Philip Carlucci², Jill Buyon³, H Michael Belmont⁴, Kelly Corbitt¹, Sara Sahl⁵, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁷, Laura Geraldino-Pardilla⁸, Yousaf Ali⁹, Ellen M. Ginzler¹⁰, Chaim Putterman¹¹, Caroline Gordon¹², Hilary Parton¹³ and Peter Izmirly³, ¹New York University, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Harbor-University of California Medical Center, Los Angeles, CA, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ¹¹Albert Einstein College of Medicine, Bronx, NY, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹³New York City Department of Health and Mental Hygiene, New York, NY
Background/Purpose: Epidemiologic data of secondary connective tissue disease and autoantibody profiles among patients with systemic lupus erythematosus (SLE) remains limited for racial/ethnic populations in the…
Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica¹, Arturo Blazquez-Navarro², Jan Sokolar³, Moritz Anft⁴, Uta Kiltz⁵, Stephanie Pfaender⁶, Elena Vidal Blanco⁷, Timm Westhoff⁸, Nina Babel⁸, Ulrik Stervbo⁹ and Xenofon Baraliakos¹⁰, ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr Universität Bochum, Herne, Germany, ⁴Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universit t Bochum, Medical Department I, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ⁷Ruhr-University Bochum, Department of Molecular and Medical Virology, Bochum, Germany, ⁸Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁹Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ¹⁰Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…
Abstract Number: 2167 • ACR Convergence 2022
Autoantibodies in Patients with Early Systemic Sclerosis in the Collaborative National Quality and Efficacy Registry
Alyssa Bosso¹, Shervin Assassi², Tracy Frech³, Jessica Gordon⁴, Elana Bernstein⁵, Carrie Richardson⁶, Nora Sandorfi⁷, Laura Hummers⁸, Ami Shah⁹, Dinesh Khanna¹⁰, Lorinda Chung¹¹, Flavia Castelino¹², Faye Hant¹³, Victoria Shanmugam¹⁴, John VanBuren¹⁵, Angela Larkin¹⁶, Luke Evnin¹⁷ and Virginia Steen¹⁸, ¹Medstar Georgetown University Hospital, Washington, DC, ²McGovern Medical School, University of Texas, Houston, TX, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Hospital for Special Surgery, New York, NY, ⁵Columbia University, New York, NY, ⁶Northwestern University, Riverside, IL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Johns Hopkins Univerisity, Baltimore, MD, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Stanford University, Stanford, CA, ¹²Massachusetts General Hospital, Boston, MA, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴George Washington University, Great Falls, VA, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶University of Utah Health, Salt Lake City, UT, ¹⁷Scleroderma Research Foundation, Brisbane, CA, ¹⁸Georgetown University School of Medicine, Washington, DC
Background/Purpose: We sought to describe the autoantibody profile of SSc patients with early disease and examine the clinical, laboratory and prognostic features associated with these…
Abstract Number: 0044 • ACR Convergence 2021
Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism
Koji Sakuraba¹, Akilan Krishnamurthy¹, Alexandra Circiumaru², Jitong Sun¹, Vijay Joshua¹, Heidi Wähämaa¹, Marianne Engström¹, Meng Sun¹, Xiaowei Zheng¹, Cheng Xu¹, khaled amara¹, Vivianne Malmström¹, Sergiu Catrina¹, Caroline Grönwall¹, Anca Catrina¹ and Bence Réthi¹, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Malondialdehyde (MDA) is a highly reactive compound generated during lipid-peroxidation in conditions associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine…
Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Thaisa Cotton¹, Marvin Fritzler², May Choi³, Boyang Zheng⁴, Omid Zahedi Niaki⁵, Louis-Pierre Grenier⁵, Evelyne Vinet⁶, Christian Pineau¹, Luck Lukusa⁷, Fares Kalache⁵ and Sasha Bernatsky¹, ¹McGill University, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University Health Centre, Mont Royal, QC, Canada, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…
Abstract Number: 0858 • ACR Convergence 2021
Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: SLE patients may have a particular propensity to some viral infections including zoster and CMV. International studies have suggested that prednisone and rituximab may…
Abstract Number: 1492 • ACR Convergence 2021
A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal
Robert Clancy¹, Miranda Marion², Hannah Ainsworth², Miao Chang¹, Timothy Howard³, Peter Izmirly⁴, Mala Masson⁵, Jill Buyon⁶ and Carl Langefeld⁷, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Wake Forest University, Quakertown, NC, ⁴New York University School of Medicine, New York, NY, ⁵NYU Grossman School Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Wake Forest University, Winston Salem, NC
Background/Purpose: Unknown factors trigger the transition of anti-Ro+ mothers of neonatal lupus (NL) children from preclinical autoimmunity to clinical disease. One candidate may be the…
Abstract Number: 0073 • ACR Convergence 2021
Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
Cecilia Chighizola¹, Francesca Pregnolato², Danieli De Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Paul R Fortin⁸, Tatsuya Atsumi⁹, Maria Efthymiou,¹⁰, Guilherme Ramires de Jesus¹¹, D. Ware Branch¹², Cecilia Nalli¹³, Michelle Petri¹⁴, Esther Rodriguez-Almaraz¹⁵, Ricard Cervera¹⁶, Yu Zuo¹⁷, Rohan Willis¹⁸, Elisa Bison¹⁹, Ian Mackie²⁰, Hannah Cohen²¹, Robert Roubey²², Doruk Erkan²³ and Maria Laura Bertolaccini²⁴, ¹University of Milan, Milan, Italy, ²Università degli Studi di Milano, Milan, Italy, ³University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸CHU de Quebec - Universite Laval, Québec City, QC, Canada, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ¹¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹²University of Utah, Salt Lake City, UT, ¹³ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Hospital Clinic Barcelona, Barcelona, Spain, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸University of Texas Medical Branch, Galveston, TX, ¹⁹University of Padova, Padova, Italy, ²⁰University College London, London, United Kingdom, ²¹Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ²²UNC, Chapel Hill, NC, ²³Hospital for Special Surgery, New York, NY, ²⁴King's College London, London, United Kingdom
Background/Purpose: Data on fluctuation of antibodies against domain 1 (anti-D1) of β2-glycoprotein I (β2GPI) are scarce. Patients with antiphospholipid syndrome (APS) and all three criteria…
Abstract Number: 0344 • ACR Convergence 2021
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
Kuniyuki Aso¹, Michihito Kono¹, Keita Ninagawa¹, Nobuya Abe¹, Yuichiro Fujieda¹, Masaru Kato¹, Olga Amengual¹, Kenji Oku¹ and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Sapporo, Japan
Background/Purpose: Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibody (Ab) is associated with widespread autonomic dysfunction in autoimmune autonomic ganglionopathy. Although it is also detected in several…
Abstract Number: 0868 • ACR Convergence 2021
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Jennifer Rogers¹, Rory Bloch², Amanda Eudy¹, David Pisetsky³, Roberta Alexander², John Conklin², Kai Sun¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²Exagen Inc., Vista, CA, ³Duke University Medical Center, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].